MCCQE1 practice questions: hypertension under the 2025 Hypertension Canada guideline
Three full clinical vignettes with worked explanations. Hypertension Canada rewrote its primary care guideline in 2025 and moved the diagnostic threshold to 130/80 mm Hg. If you are revising from an American question bank, or from the older Canadian recommendations, you are carrying at least one wrong number into the exam.
These are free samples. The full platform builds papers from the Canadian guidelines, grades them, and tracks every topic you get wrong.
What the 2025 guideline changed
The 2025 Hypertension Canada guideline was written for primary care and deliberately collapsed a complicated set of thresholds and targets into one of each. Two things make it high-yield for MCCQE1 Part 1. First, it is recent, so a candidate revising from older material is working from superseded numbers. Second, it separates three ideas that question writers love to blur together: the pressure at which you diagnose hypertension, the pressure at which you start a drug, and the pressure you treat towards. Those are three different numbers.
The numbers, in the order a question will test them
| Diagnostic threshold | 130/80 mm Hg or higher, measured with a validated device under optimal conditions. A strong recommendation on moderate-certainty evidence. |
|---|---|
| Confirming the diagnosis | Out-of-office measurement is recommended — ambulatory or home monitoring — both to confirm the diagnosis and to pick up white-coat and masked hypertension. |
| Lifestyle change | Recommended for all adults with hypertension, with or without medication. |
| When to start a drug | BP 140/90 or higher; or systolic 130–139 in an adult at high cardiovascular disease risk. |
| What counts as high cardiovascular disease risk | The guideline sets this out in a box rather than leaving it to judgement. Any one of: established cardiovascular disease (coronary artery disease, heart failure, cerebrovascular disease or peripheral artery disease); diabetes, type 1 or type 2; chronic kidney disease (eGFR below 60 mL/min/1.73 m², or albuminuria of 3 mg/mmol or more); a 10-year Framingham Risk Score of 20% or more; or age 75 or over. |
| Systolic 130–139 and not at high risk | Lifestyle change alone, and reassess the blood pressure in 3 to 6 months. No drug yet. |
| Treatment target | Systolic below 130 mm Hg, provided treatment is well tolerated. |
| First drug step | Low-dose combination therapy, ideally as a single-pill combination, drawn from two of three complementary classes: an ACE inhibitor or an ARB; a thiazide or thiazide-like diuretic; a long-acting dihydropyridine calcium channel blocker. An ACE inhibitor and an ARB are not combined with each other. |
The guideline is candid about the cost of the lower threshold: it accepts that defining hypertension at 130/80 will increase the number of people labelled as having hypertension. Note what does not follow. The treatment threshold did not move with the diagnostic one, so most people newly meeting the definition are candidates for lifestyle change and reassessment rather than for a drug. Keeping those two apart is what a well-written question on this guideline is usually testing.
Three practice questions
A 54-year-old woman with no past medical history attends for a routine visit. She takes no medication, does not smoke, and has no family history of premature cardiovascular disease. Automated office blood pressure is 136/84 mm Hg, and a repeat reading at the same visit is 134/86 mm Hg. Her BMI is 27 kg/m². Physical examination is otherwise normal. Which of the following is the most appropriate next step?
- A. Diagnose hypertension and start a low-dose single-pill combination today
- B. Arrange out-of-office blood pressure measurement and begin lifestyle change now
- C. Reassure her that her blood pressure is normal and recheck in one year
- D. Start antihypertensive therapy aiming for a systolic pressure below 120 mm Hg
- E. Repeat office readings monthly for six months before making any decision
Show the answer and explanation
Correct answer: B. Arrange out-of-office blood pressure measurement and begin lifestyle change now
Her readings sit at or above the 2025 diagnostic threshold of 130/80 mm Hg, so this is not a normal blood pressure and it cannot be left for a year. But two things follow from the guideline rather than from instinct.
First, the diagnosis is confirmed out of office. Ambulatory or home monitoring is recommended both to establish the diagnosis and to identify white-coat hypertension — which matters a great deal here, because the alternative is committing a 54-year-old to lifelong therapy on the strength of two clinic readings.
Second, she does not yet meet the threshold for drug therapy. Her systolic pressure is in the 130–139 band, and pharmacotherapy in that band is reserved for adults at high cardiovascular risk, and the guideline lists what that means: established cardiovascular disease, diabetes, chronic kidney disease, a 10-year Framingham Risk Score of 20% or more, or age 75 or over. She has none of them. For precisely her situation — systolic 130–139 and not at high risk — the guideline asks for lifestyle change alone with the pressure reassessed in three to six months. Lifestyle change is recommended for everyone with hypertension, and it starts today.
Why the other options are wrong
- A. Right threshold, wrong action. 136/84 is enough to suspect and investigate hypertension, not enough to start a drug in someone at low cardiovascular risk, and the diagnosis has not yet been confirmed out of office.
- C. This is the single most common error on this topic, and it comes from carrying the old 140/90 frame forward. Under the 2025 guideline 134/86 is not normal.
- D. Below 120 is not the Canadian target. The target is systolic below 130. A candidate who picks this is answering from an American trial-derived number rather than from Hypertension Canada.
- E. Six months of office readings is both slower and less accurate than the recommended route. Office measurement cannot distinguish white-coat hypertension however many times you repeat it.
A 66-year-old man had an anterior myocardial infarction three years ago and is on secondary prevention therapy. He has spent the last three months on a structured programme of sodium reduction, weight loss and regular aerobic exercise. His home blood pressure average over seven days is 134/80 mm Hg, confirmed on a validated upper-arm device. He has no symptoms, and renal function and electrolytes are normal. Which of the following is the most appropriate management?
- A. Continue lifestyle measures alone and reassess in six months
- B. Start antihypertensive drug therapy now
- C. No action is needed, because his blood pressure is below 140/90 mm Hg
- D. Start drug therapy only if his systolic pressure later exceeds 140 mm Hg
- E. Start intensive therapy targeting a systolic pressure below 120 mm Hg
Show the answer and explanation
Correct answer: B. Start antihypertensive drug therapy now
This is the second limb of the pharmacotherapy recommendation, and it is where the guideline rewards you for reading carefully. His systolic pressure of 134 sits in the 130–139 band, which on its own would not call for a drug. Established cardiovascular disease puts him at high cardiovascular risk, and for adults with systolic 130–139 at high risk, drug therapy is recommended.
Notice also what the stem has already done for you: three months of genuine lifestyle change, and a seven-day home average on a validated device. The question has removed every excuse for waiting. Treatment then aims at a systolic below 130, as tolerated.
Why the other options are wrong
- A. Lifestyle change continues, but it has already been given a fair trial and has not brought him below 130. Continuing it alone leaves a high-risk patient above target.
- C. The 140/90 figure is the threshold for starting a drug in someone without high cardiovascular risk. Applying it to a man with a prior myocardial infarction misses the high-risk limb of the recommendation entirely.
- D. This defers treatment on the basis of a threshold that does not apply to him. The point of the high-risk limb is that waiting for 140 is the wrong plan in this patient.
- E. Below 120 overstates the Canadian target, which is systolic below 130 where tolerated. Choosing a more aggressive number than the guideline sets is still a wrong answer.
A 48-year-old man has hypertension confirmed by ambulatory monitoring, with a daytime average of 148/94 mm Hg. He has no diabetes, no chronic kidney disease and no history of cardiovascular disease. There is no contraindication to any first-line antihypertensive class, and he is willing to take medication. Which plan is most consistent with the 2025 Hypertension Canada guideline?
- A. A single agent at maximum dose, titrated over the next six months
- B. Low-dose combination therapy, ideally as a single-pill combination, aiming for a systolic pressure below 130 mm Hg
- C. Lifestyle measures alone for twelve months before considering any drug
- D. Drug therapy titrated to a systolic pressure below 140 mm Hg, then held there
- E. Drug therapy titrated to below 120/70 mm Hg in every adult
Show the answer and explanation
Correct answer: B. Low-dose combination therapy, ideally as a single-pill combination, aiming for a systolic pressure below 130 mm Hg
Two separate decisions are being tested, and the guideline answers both. He is above 140/90, so drug therapy is recommended regardless of his cardiovascular risk. And when a drug is started, the 2025 guideline favours beginning with low-dose combination therapy, ideally delivered as a single-pill combination, rather than pushing one agent to its ceiling.
The target does not change because he is low risk: systolic below 130, as tolerated. The single target was a deliberate simplification — one threshold, one target — made in response to what primary care asked for.
Why the other options are wrong
- A. Maximising one agent before adding a second is the older sequential approach. The 2025 guideline favours low-dose combination therapy, which gets more blood pressure lowering with fewer dose-related adverse effects.
- C. At 148/94 he is above the threshold for pharmacotherapy. Lifestyle change is recommended alongside the drug, not as a reason to withhold it for a year.
- D. Stopping at below 140 confuses the initiation threshold with the target. 140/90 is where you start treating; below 130 systolic is where you are trying to get to.
- E. No Canadian target is set at below 120/70 for every adult. Inventing a stricter number than the guideline is as wrong as using a looser one.
Four traps this topic sets
1. Three numbers, three jobs. 130/80 diagnoses. 140/90 (or 130–139 with high risk) starts a drug. Below 130 systolic is the target. Most wrong answers on this topic are a real guideline number applied to the wrong question.
2. The old Canadian frame. If your revision notes predate 2025, your diagnostic threshold is wrong. A reading of 134/86 is no longer a normal blood pressure in Canada.
3. The American frame. The 2025 AHA/ACC guideline also uses 130/80 for diagnosis and for treatment initiation, so the two now agree on diagnosis — which makes it easy to assume they agree on everything. The Canadian initiation rule is its own: 140/90, or 130–139 with high cardiovascular risk. Meanwhile the 2023 European guideline still defines hypertension at 140/90, so European material will give you a third answer.
4. One visit is not a diagnosis. Out-of-office measurement is recommended to confirm. A stem that gives you a single office reading and asks you to commit to lifelong therapy is usually testing whether you will.
Sources
Every figure on this page is traceable to one of these. Guidelines are revised — open the source before you commit a number to memory.
- Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care (CMAJ, 2025) — the full guideline, including the strength of each recommendation
- Hypertension Canada — Diagnosis — the issuing body's own summary of the diagnostic recommendations
- Hypertension Canada guideline, Canadian Family Physician release — the same guideline as published for family physicians
- 2025 primary care guideline: routine screening tests and adaptation process (supplementary tables, PDF) — the baseline investigations expected at diagnosis
More free MCCQE1 practice questions
- Gestational diabetes screening and the two Canadian threshold setsThe 50 g glucose challenge bands, the preferred and alternate 75 g OGTT criteria, and why the same blood results can produce two different diagnoses.
- Diabetes Canada: diagnosis, A1C targets and screening intervalsThe four diagnostic tests, why the target is not 7.0% for everybody, and when screening starts outside pregnancy.
- Cancer screening in Canada, and where the provinces disagreeCervical screening from 25, the FIT interval, mammography ages, and how to answer when the national guideline and your province differ.
- Prenatal care and screening under the SOGC guidelinesGroup B streptococcus at 35 to 37 weeks, Rh immunoglobulin at 28 weeks, and folic acid dosing that is not what most sources say.
See all free MCCQE1 practice topics →
About these practice pages
MCCQE1 Tutor is a Canadian-guideline preparation platform for the Medical Council of Canada Qualifying Examination Part 1, built by AYRIQ Technologies. The questions on this page were written for this page and are given away free. They are not drawn from the subscriber question bank, so working through them uses up nothing you have paid for.
Practising on Canadian numbers is the whole point. Everything here is free; the platform is where it becomes a study plan.